• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

BerGenBio

Selective AXL inhibitors

  • About BerGenBio
    • About BerGenBio
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline overview
    • bemcentinib | NSCLC
    • bemcentinib | COVID-19
    • bemcentinib | Melanoma
    • bemcentinib | AML
    • BGB149
    • BGB601
    • Discovery
    • Publications
    • Expanded access policy
  • Media Centre
    • News
    • Events
    • COVID-19 Media Pack
    • Media Contacts
  • Investors
    • Share Information
    • Largest Shareholders
    • Stock Exchange Notices
    • Presentations
    • Financial Reports
    • Financial Calendar
    • Analysts
    • General Meetings
    • Corporate Governance
    • IR Contacts
  • Careers
  • Contact
Home  /  Media Centre  /  News  /  Page 2

News

202020192018201720162015

UPDATE ON BEMCENTINIB’S INVOLVEMENT IN POTENTIAL TREATMENT OF COVID-19 PANDEMIC

July 28, 2020

BerGenBio in late stage set-up phase to sponsor and conduct a clinical study using bemcentinib…

Read More

BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN RECURRENT GLIOBLASTOMA INVESTIGATOR SPONSORED PHASE I/II STUDY ASSESSING SELECTIVE AXL INHIBITOR BEMCENTINIB

July 20, 2020

Bergen, Norway, 20 July 2020 –BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More

BERGENBIO ANNOUNCES POSITIVE interim CLINICAL AND TRANSlaTIONAL DATA from Phase II trial of BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN checkpoint inhibitor refractory NSCLC PATIENTS

June 25, 2020

6 of 7 checkpoint inhibitor refractory cAXL-positive patients report clinical benefit 12 evaluable patients for cAXL…

Read More

BERGENBIO ANNOUNCES CHANGE TO PRESENTATION TIME AT Next Gen Immuno-Oncology Congress

June 24, 2020

Bergen, Norway, 24 June 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BerGenBio to Present at the Upcoming Virtual European Biotech Investor Day 2020

June 23, 2020

Bergen, Norway, June 23, 2020 – BerGenBio, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors…

Read More

BERGENBIO TO PRESENT TOP LINE TRANSLATIONAL PHASE II DATA WITH BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN NSCLC PATIENTS AT Next Gen Immuno-Oncology Congress

June 15, 2020

Bergen, Norway, 15 June 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More
  • Previous
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Interim pages omitted …
  • Go to page 29
  • NEXT

Primary Sidebar

  • Media Centre
  • News
  • Events
  • COVID-19 Media Pack
  • Media Contacts

News Subscription

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email.

We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.

Footer

Key Information

  • Pipeline
  • Investors
  • News
  • Presentations
  • Management Team

Useful Information

  • Privacy Policy
  • Terms of Use
  • Job Applicant Privacy Notice
  • Site Map

Get In Touch

BerGenBio ASA
Company registration number 992 219 688

Jonas Lies vei 91, 5009 Bergen, Norway

www.bergenbio.com

+ 47 559 61 159

Copyright © 2017 BerGenBio ASA. All right reserved. Designed by Utopian Designs